A woman with recurrent diarrhea is prescribed a broad-spectrum antibiotic. Which of the following is not true regarding Clostridium difficile infection?

Correct Answer: A. IgM assay is used to confirm the diagnosis

The diagnosis of Clostridium difficile infection (CDI) is NOT confirmed by IgM assay. The gold standard for CDI diagnosis in India and globally is nucleic acid amplification testing (NAAT) or PCR for C. difficile toxin genes (toxA and toxB), which detects toxigenic strains with high sensitivity and specificity. Enzyme immunoassay (EIA) for toxins A and B is also acceptable but less sensitive than NAAT. IgM antibodies indicate past or recent infection but do not confirm active CDI because they persist and do not correlate with clinical disease. In Indian clinical practice, stool PCR or toxin EIA are the standard confirmatory tests recommended by ICMR guidelines. IgM serology is not used for diagnosis of CDI; it may be used in epidemiological surveys but has no role in confirming active infection in a symptomatic patient with antibiotic-associated diarrhea.

Why the other options are wrong

B. Pseudomembrane is a layer of inflammatory — This statement is TRUE. Pseudomembranes in CDI are composed of fibrin, mucus, necrotic epithelial cells, and inflammatory exudate—not true membranes. They are pathognomonic for fulminant CDI and represent severe mucosal injury. This is a well-established histopathological finding in C. difficile colitis and is correctly described as an inflammatory layer. C. It is toxin mediated — This statement is TRUE. C. difficile pathogenesis is entirely toxin-mediated. Toxin A (enterotoxin) and Toxin B (cytotoxin) are the virulence factors that cause mucosal damage, inflammation, and diarrhea. Only toxigenic strains cause disease. This is fundamental to CDI pathophysiology and is a core concept in medical microbiology. D. Oral fidaxomicin is used for treatment — This statement is TRUE. Fidaxomicin is a macrocyclic antibiotic and is the preferred first-line agent for CDI in India and globally, especially for severe or recurrent cases. It has superior efficacy and lower recurrence rates compared to vancomycin or metronidazole. Oral administration ensures high colonic concentration. This aligns with current Indian clinical practice guidelines.

High-Yield Facts

Mnemonics

CDI Diagnosis: NOT IgM NAAT (PCR) > EIA (toxin) >> IgM (serology). Remember: IgM = past, NAAT = present. Use this when a question offers serology as a diagnostic test for CDI. CDI Treatment Ladder Mild-Moderate: Metronidazole oral. Severe/Recurrent: Fidaxomicin or Vancomycin oral. Fulminant: Vancomycin IV + metronidazole. Fidaxomicin is preferred when available in India due to lower recurrence.

NBE Trap

NBE pairs "IgM assay" with "diagnosis" to trap students who confuse serological markers (which indicate exposure) with diagnostic tests (which detect active toxin or organism). The question tests whether students know that CDI diagnosis requires toxin/NAAT detection, not antibody serology.

Clinical Pearl

In Indian hospitals, when a patient develops diarrhea 3–5 days after starting broad-spectrum antibiotics (especially fluoroquinolones or clindamycin), suspect CDI and order stool PCR or toxin EIA—not serology. Serology will only tell you if the patient has been exposed to C. difficile, not whether they have active infection. Start fidaxomicin 200 mg BD orally if available; if not, use metronidazole 400 mg TDS for mild cases.

_Reference: Jawetz, Melnick & Adelberg's Medical Microbiology (Ch. 23 – Clostridium difficile); Harrison's Principles of Internal Medicine (Ch. 157 – Clostridioides difficile Infection)_